Shareholder Alert: Robbins LLP Announces Another Complaint Filed Against Portola Pharmaceuticals, Inc. (PTLA)

Shareholders Rights law firm Robbins LLP announces that another purchaser of Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934 and Securities Act of 1933 between January 8, 2019 and February 26, 2020. Portola Pharmaceuticals is a biopharmaceutical company that develops and commercializes treatments for thrombosis and other hematologic diseases. Its lead product is Andexxa.

If you suffered a loss as a result of Portola's misconduct, click here.

Portola Pharmaceuticals, Inc. (PTLA) Accused of Misleading Shareholders

According to the complaint, throughout the relevant period, Portola touted Andexxa's revenues and future prospects, calling it one of the most successful drug launches in history with "deepening utilization" and increasing reorder rates, resulting in robust revenue growth for Portola. However, in reality, Portola's high wholesale price of $49,500 per dose caused many hospitals to curtail their use of the drug, materially diminishing the demand for Andexxa. Then, on January 9, 2020, Portola announced global revenues of Andexxa that fell significantly short of analysts' expectations at $28 million for the fourth quarter, citing flattening Andexxa demand that also resulted in a $5 million charge for unused and returned Andexxa. Portola reported a fourth quarter 2019 loss of $96.7 million on February 26, 2020, citing a $27.5 million charge arising from its discontinuation of its product Bevyxxa to help the Company focus on its efforts with Andexxa. Following these disclosures, Portola's share price fell $12.33 per share, or almost 50%, to close at $10.17 per share.

Portola Pharmaceuticals, Inc. (PTLA) Shareholders Have Legal Options

Robbins LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200303006005/en/

Leo Kandinov Robbins LLP 5040 Shoreham Place San Diego, CA 92122 lkandinov@robbinsllp.com (619) 525-3990 or Toll Free (800) 350-6003 www.robbinsllp.com

Portola Pharmaceuticals (NASDAQ:PTLA)
Historical Stock Chart
From Mar 2024 to Apr 2024